Nektar Therapeutics (NKTR) EBIT (2016 - 2025)
Historic EBIT for Nektar Therapeutics (NKTR) over the last 16 years, with Q3 2025 value amounting to -$31.7 million.
- Nektar Therapeutics' EBIT rose 778.28% to -$31.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$98.1 million, marking a year-over-year increase of 3591.34%. This contributed to the annual value of -$105.2 million for FY2024, which is 6010.45% up from last year.
- Per Nektar Therapeutics' latest filing, its EBIT stood at -$31.7 million for Q3 2025, which was up 778.28% from -$36.2 million recorded in Q2 2025.
- In the past 5 years, Nektar Therapeutics' EBIT registered a high of $14.3 million during Q4 2024, and its lowest value of -$152.8 million during Q2 2022.
- Its 5-year average for EBIT is -$68.6 million, with a median of -$50.6 million in 2023.
- Per our database at Business Quant, Nektar Therapeutics' EBIT tumbled by 4181.76% in 2021 and then soared by 14281.58% in 2024.
- Over the past 5 years, Nektar Therapeutics' EBIT (Quarter) stood at -$112.9 million in 2021, then soared by 53.53% to -$52.5 million in 2022, then soared by 36.13% to -$33.5 million in 2023, then skyrocketed by 142.82% to $14.3 million in 2024, then crashed by 320.74% to -$31.7 million in 2025.
- Its EBIT stands at -$31.7 million for Q3 2025, versus -$36.2 million for Q2 2025 and -$44.5 million for Q1 2025.